Shifting terrain in the regulation of off-label promotion of pharmaceuticals

New England Journal of Medicine

Volumn 360, Issue 15, 2009, Pages 1557-1566

  Mello, Michelle M ^a   Studdert, David M ^b   Brennan, Troyen A ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ARSENIC TRIOXIDE; GABAPENTIN; GAMMA1B INTERFERON; HUMAN GROWTH HORMONE; OLANZAPINE; OXYBATE SODIUM; OXYCODONE; PAROXETINE; RECOMBINANT ALPHA2B INTERFERON; ROFECOXIB; TEMOZOLOMIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLADDER CANCER; BRAIN CANCER; CATAPLEXY; CHRONIC HEPATITIS; CHRONIC PAIN; CONDYLOMA ACUMINATUM; DEMENTIA; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; EPILEPSY; FATIGUE; FIBROMYALGIA; FIBROSING ALVEOLITIS; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; GRANULOMATOSIS; HAIRY CELL LEUKEMIA; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HUMAN; INSOMNIA; KAPOSI SARCOMA; LAW ENFORCEMENT; LEUKEMIA; LIPODYSTROPHY; MELANOMA; MIGRAINE; NARCOLEPSY; OFF LABEL DRUG USE; OSTEOPOROSIS; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; WASTING SYNDROME; DRUG LABELING; GOVERNMENT REGULATION; HISTORY; LEGAL ASPECT; MARKETING; MEDICAL EDUCATION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PUBLISHING; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; EDUCATION, MEDICAL, CONTINUING; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; HEALTH POLICY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MARKETING; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLICATION BIAS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 64349114018     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMhle0807695     Document Type: Article

References (57)

1. Food and Drug Administration. Guidance for industry on good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices: availability. Fed Regist 2009;74(8):1694-1695
2. Office of the Commissioner, Office of Policy. Guidance for industry: good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices. Silver Spring, MD: Food and Drug Administration, January 2009. (Accessed March 20, 2009, at http://www.fda.gov/ OHRMS/DOCKETS/98fr/FDA-2008-D-0053-gdl.pdf.)
3. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026
4. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006;5:703-718 (Pubitemid 44322888)
5. Prescription drugs: FDA's oversight of the promotion of drugs for off-label uses. Washington, DC: Government Accountability Office, July 2008. (Publication no. GAO-08-835.)
6. Lurie P, Tran T, Wolfe SM, Goodman R. Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting. J Public Health Policy 2005;26:389-399 (Pubitemid 43003341)
7. Abrams T. The regulation of prescription drug promotion. In: Santoro MA, Gorrie TM, eds. Ethics and the pharmaceutical industry. New York: Cambridge University Press, 2005:153-168
8. Danzis SD. Off-label communications and prescription drugs. In: Santoro MA, Gorrie TM, eds. Ethics and the pharmaceutical industry. New York: Cambridge University Press, 2005:184-195
9. Federal Food, Drugs, and Cosmetics Act, 21 U.S.C. 355(a) (2008).
10. Definitions and interpretations, 21 C.F.R. § 310.3(h) (2008).
11. Prescription-drug advertisements, 21 C.F.R. § 202.1(e)(4) (2008).
12. Federal Food, Drugs, and Cosmetics Act, 21 U.S.C. 331 (2008).
13. Washington Legal Foundation v. Henney, 202 F.3d 331 (D.C. Cir. 2000).
14. Kordel v. United States, 335 U.S. 345 (1948).
15. Prescription-drug advertisements, 21 C.F.R. § 202.1(l)(2) (2008).
16. Food and Drug Administration. Citizen petition regarding the Food and Drug Administration's policy on promotion of unapproved uses of approved drugs and devices; request for comments. Fed Regist 1994;59(222):59820-59826
17. Fleisher LD, Dechene JC. Telemedicine and e-health law. New York: Law Journal Seminars Press, 2004.
18. Washington Legal Foundation v. Friedman, 36 F. Supp. 2d 16 (D.D.C. 1999).
19. Food and Drug Administration. Draft policy statement on industry-supported scientific and educational activities: notice. Fed Regist 1992;57(229):56412-56414
20. Idem. Advertising and promotion; guidances. Fed Regist 1996;61(196):52800-52801
21. Idem. Final guidance on industry-supported scientific and educational activities. Fed Regist 1997;62(232):64073.
22. Idem. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices: final rule. Fed Regist 1998;63(224):64556-64588
23. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices, 21 C.F.R. § 99 (2008).
24. Kesselheim AS, Avorn J. Pharmaceutical promotion to physicians and First Amendment rights. N Engl J Med 2008;358:1727-1732
25. Thompson v. Western States Medical Center, 535 U.S. 357 (2002).
26. Washington Legal Foundation v. Friedman, 13 F. Supp. 2d 51 (D.D.C. 1998).
27. United States v. Caputo, 288 F Supp 2d 912 (N.D. Ill. 2003).
28. Mundy A. Off-label use of drugs gets a push - Big Pharma lobbies Washington to relax rules on marketing. Wall Street Journal. April 18, 2008:A14.
29. Markus CM, Bragg JL, Tseng EH, Lorell BH. FDA issues draft guidance for dissemination of off-label reprints. Health Lawyers Weekly. April 4, 2008. (Available at http://www.healthlawyers.org.)
30. Saul S. Setback for effort to ease rules on promoting drugs. New York Times. April 19, 2008:B3.
31. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-1812
32. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med 2008;149:251-258
33. Greenland P, Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA 2008;299:953-955
34. Kesselheim AS, Avorn J. Pharmaceutical promotion and First Amendment rights. N Engl J Med 2008;359:536-537
35. LexisNexis home page. (Accessed March 20, 2009, at http://www.lexis.com.)
36. Department of Justice. Bristol-Myers Squibb to pay more than $515 million to resolve allegations of illegal drug marketing and pricing. September 28, 2007. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/2007/September/ 07-civ-782.html.)
37. Idem. Otsuka to pay more than $4 million to resolve off-label marketing allegations involving Abilify. March 27, 2008. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/pr/2008/March/08-civ-244.html.)
38. Idem. Cell Therapeutics, Inc. to pay United States $10.5 million to resolve claims for illegal marketing of cancer drug. April 17, 2007. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/pr/2007/April/07-civ-258. html.)
39. Idem. Eli Lilly and Company agrees to pay $1.415 billion to resolve allegations of off-label promotion of Zyprexa. January 15, 2009. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/pr/2009/January/09-civ- 038.html.)
40. Idem. Biopharmaceutical firm Intermune to pay U.S. over $36 million for illegal promotion and marketing of drug Actimmune. October 26, 2006. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/pr/2006/October/06-civ- 728.html.)
41. Idem. Jazz Pharmaceuticals, Inc. agrees to pay $20 million to resolve criminal and civil allegations in "off-label" marketing investigation. July 13, 2007. (Accessed March 20, 2009, at http://www.usdoj.gov/ usao/nye/pr/2007/2007jul13a.html.)
42. Idem. Warner-Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion. May 13, 2004. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/pr/2004/May/04-civ-322. htm.)
43. Idem. The Purdue Frederick Company, Inc. and top executives plead guilty to misbranding OxyContin; will pay over $600 million. May 10, 2007. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/pr/2004/May/04-civ-322. htm.)
44. Idem. Schering to pay $435 million for the improper marketing of drugs and Medicaid fraud. August 29, 2006. (Accessed March 20, 2009, at http://www.usdoj.gov/usao/ma/Press%20Office%20-%20Press%20Release%20Files/ Schering-Plough/press%20release.pdf.)
45. Idem. Serono to pay $704 million for the illegal marketing of AIDS drug. October 15, 2005. (Accessed March 20, 2009, at http://www.usdoj.gov/opa/ pr/2005/October/05-civ-545.html.)
46. False Claims Act, 31 U.S.C. § 3729 (2008).
47. Helm KA. Protecting public health from outside the physician's office: a century of FDA regulation from drug safety labeling to off-label drug promotion. Fordham Intellect Prop Media Entertainment Law J 2007;18:117-187
48. Orsini-Meinhard K. Cell Therapeutics to pay $10.5 million to settle feds' suit. Seattle Times. April 18, 2007:D1.
49. Berenson A. Indictment of doctor tests drug marketing rules. New York Times. July 22, 2006.
50. United States ex rel. Franklin v. Parke-Davis, 2003 U.S. Dist. LEXIS 15754 (D. Mass. 2003).
51. Kesselheim AS, Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Intern Med 2008;149:342-349
52. Loucks MK. Pros and cons of off-label promotion investigations and prosecutions. Food Drug Law J 2006;61:577-583
53. Draft version of FDA guide on journal dissemination sparks debate. Vol.13. FDA Week. 2007. (Arlington, VA: Inside Washington.)
54. Psaty BM, Ray W. FDA guidance on off-label promotion and the state of the literature from sponsors. JAMA 2008;299:1949-1951.
55. Stafford RS. Regulating off-label drug use - rethinking the role of the FDA. N Engl J Med 2008;358:1427-1429
56. Waxman HA. Letter to the Hon. Andrew C. von Eschenbach. November 30, 2007. (Accessed March 20, 2009, at http://oversight.house.gov/documents/ 20071130102744.pdf.)
57. Angell M. Industry-sponsored clinical research: a broken system. JAMA 2008;300:1069-1071